The Future of Pharmaceuticals: AI Drug Discovery & COVID-19 Treatments
A Step Forward in Medicine with Artificial Intelligence and Machine Learning
DOI:
https://doi.org/10.47611/jsrhs.v11i3.3046Keywords:
Artificial Intelligence, Drug Discovery, COVID-19 Treatments, COVID-19 VaccineAbstract
AI Drug Discovery (AIDD) is the implementation of artificial intelligence and computational modeling in the process of finding the ideal medicinal drug for a given ailment; its primary benefit is exponentially speeding up the drug discovery process to about 1 to 2 years, whereas the traditional steps of lead optimization, clinical trials, regulatory approval, and medicinal manufacturing would span approximately 10 years. The COVID-19 pandemic could have been far worse and for a far longer duration if AIDD was not utilized, demonstrating great technological advancement in the field of medicine from the Spanish Flu pandemic in 1918. The benefits of AIDD in areas outside of COVID-19 can be seen in how Wisecube AI developed treatments for Alzheimer’s disease, Schrodinger AI was able to suppress tumors through protein analysis, and the drug discovery database of the scientific community is expanded through AIDD algorithms produced by companies like Standigm and Cytoreason. The idea of repurposing, the use of preexisting drugs to be slightly altered to cover completely different ailments, is also enhanced. In terms of COVID-19 treatments, however, AIDD is used to attack the virus through all forms of vaccinology, including protein-based, RNA-based, and mRNA-based vaccines. The Pfizer and Moderna vaccines are recommended the most by the CDC because of their effective innovation with AIDD in mRNA vaccinology. Simply, AIDD accelerates the R&D timeline of finding drug treatments for the prominent diseases that concern global intervention, and the world nears medicinal mastery with the utilization of computers.
Downloads
References or Bibliography
Joi, P. (2021, April 28). How are vaccines made? Gavi, the Vaccine Alliance. Retrieved December 30, 2021, from https://www.gavi.org/vaccineswork/how-are-vaccines-made
JHU. (2021). Vaccines. Johns Hopkins Coronavirus Resource Center. Retrieved December 30, 2021, from https://coronavirus.jhu.edu/vaccines
Yang D, Leibowitz JL. The structure and functions of coronavirus genomic 3' and 5' ends. Virus Res. 2015 Aug 3;206:120-33. doi: 10.1016/j.virusres.2015.02.025. Epub 2015 Feb 28. PMID: 25736566; PMCID: PMC4476908.
Cuffari, B. (2021, February 3). Understanding lead optimization. AZO Life Sciences. Retrieved December 30, 2021, from https://www.azolifesciences.com/article/Understanding-Lead-Optimization.aspx
Sullivan, T. (2019). A Tough Road: Cost To Develop One New Drug Is $2.6 Billion; Approval Rate for Drugs Entering Clinical Development is Less Than 12%. Policy and Medicine. https://www.policymed.com/2014/12/a-tough-road-cost-to-develop-one-new-drug-is-26-billion-approval-rate-for-drugs-entering-clinical-de.html
Takebe, T., Imai, R., & Ono, S. (2018). The Current Status of Drug Discovery and Development as Originated in United States Academia: The Influence of Industrial and Academic Collaboration on Drug Discovery and Development. Clinical and translational science, 11(6), 597–606. https://doi.org/10.1111/cts.12577
NHS. (2021). Causes of Alzheimer's Disease. NHS Choices. Retrieved December 30, 2021, from https://www.nhs.uk/conditions/alzheimers-disease/causes/
Alzheimer's Association. (2021). 2021 Alzheimer’s Disease Facts and figures. Alz.org. Retrieved December 30, 2021, from https://www.alz.org/media/Documents/alzheimers-facts-and-figures.pdf
Alzheimer’s Society. (2014). Factsheet Drug Treatments for Alzheimer’s Disease. alzheimers.org.uk. Retrieved December 30, 2021, from https://www.alzheimers.org.uk/sites/default/files/pdf/factsheet_drug_treatments_for_alzheimers_disease.pdf
WisecubeAI. (2021, December 14). Curing alzheimers using AI and knowledge graphs. YouTube. Retrieved December 30, 2021, from https://www.youtube.com/watch?v=ID014Fs5MLU
Kanungo, J., Zheng, Y. L., Amin, N. D., & Pant, H. C. (2009). Targeting Cdk5 activity in neuronal degeneration and regeneration. Cellular and molecular neurobiology, 29(8), 1073–1080. https://doi.org/10.1007/s10571-009-9410-6
Paul R. Leger, Dennis X. Hu, Berenger Biannic, Minna Bui, Xinping Han, Emily Karbarz, Jack Maung, Akinori Okano, Maksim Osipov, Grant M. Shibuya, Kyle Young, Christopher Higgs, Betty Abraham, Delia Bradford, Cynthia Cho, Christophe Colas, Scott Jacobson, . (2020). Discovery of potent, selective, and orally bioavailable inhibitors of USP7 with in vivo antitumor activity. ACS Publications. Retrieved December 30, 2021, from https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c00245
Higgs, C. (2020). Understanding water interaction leads to the discovery of a new class of reversible USP7 inhibitors that suppress tumor growth. Understanding Water Interaction Leads to the Discovery of a New Class of Reversible USP7 Inhibitors that Suppress Tumor Growth | Schrödinger. Retrieved December 30, 2021, from https://www.schrodinger.com/science-articles/usp7-inhibitors-paper
Kim, J. (2015). Standigm ASK. Standigm: The Workflow AI Drug Discovery Company. Retrieved December 30, 2021, from https://www.standigm.com/main
Standigm. (2015). iCLUE&ASK Beta. ICLUE&Ask. Retrieved December 30, 2021, from https://icluenask.standigm.com/search/analysis/result/0/Default%20DB/12276/MONDO:0100096/COVID-19
Alpert, A., Nahman, O., Starosvetsky, E., Hayun, M., Curiel, T. J., Ofran, Y., & Shen-Orr, S. S. (2021, October 7). Alignment of single-cell trajectories by tuMap enables high-resolution quantitative comparison of cancer samples. Cell Systems. Retrieved December 30, 2021, from https://doi.org/10.1016/j.cels.2021.09.003
Good, Z., Sarno, J., Jager, A. et al. Single-cell developmental classification of B cell precursor acute lymphoblastic leukemia at diagnosis reveals predictors of relapse. Nat Med 24, 474–483 (2018). https://doi.org/10.1038/nm.4505
Zhou Y, Wang F, Tang J, Nussinov R, Cheng F. Artificial intelligence in COVID-19 drug repurposing. Lancet Digit Health. 2020 Dec;2(12):e667-e676. doi: 10.1016/S2589-7500(20)30192-8. Epub 2020 Sep 18. PMID: 32984792; PMCID: PMC7500917.
Reddy, A. S., & Zhang, S. (2013). Polypharmacology: drug discovery for the future. Expert review of clinical pharmacology, 6(1), 41–47. https://doi.org/10.1586/ecp.12.74
Jimenez, D. (2021). Healx: AI-driven drug repurposing for Rare disease. pharmaceutical technology. Retrieved December 30, 2021, from https://www.pharmaceutical-technology.com/analysis/healx-ai-drug-repurposing-rare-disease/
Tanoli Z, Vähä-Koskela M, Aittokallio T. Artificial intelligence, machine learning, and drug repurposing in cancer. Expert Opin Drug Discov. 2021 Sep;16(9):977-989. doi: 10.1080/17460441.2021.1883585. Epub 2021 Feb 12. PMID: 33543671.
Keshavarzi Arshadi, A., Webb, J., Salem, M., Cruz, E., Calad-Thomson, S., Ghadirian, N., Collins, J., Diez-Cecilia, E., Kelly, B., Goodarzi, H., & Yuan, J. S. (1AD, January 1). Artificial Intelligence for covid-19 drug discovery and vaccine development. Frontiers. Retrieved December 30, 2021, from https://www.frontiersin.org/articles/10.3389/frai.2020.00065/full#B153
MediLexicon International. (2021). Covid-19 vaccine: How was it developed so fast? Medical News Today. Retrieved December 30, 2021, from https://www.medicalnewstoday.com/articles/how-did-we-develop-a-covid-19-vaccine-so-quickly
Katella, K. (2021, December 17). Comparing the COVID-19 vaccines: How are they different? Yale Medicine. Retrieved December 30, 2021, from https://www.yalemedicine.org/news/covid-19-vaccine-comparison
The Children's Hospital of Philadelphia. (2014, November 19). How are vaccines made? Children's Hospital of Philadelphia. Retrieved December 30, 2021, from https://www.chop.edu/centers-programs/vaccine-education-center/making-vaccines/how-are-vaccines-made
The Children's Hospital of Philadelphia. (2020, November 13). How do mRNA vaccines work? Children's Hospital of Philadelphia. Retrieved December 30, 2021, from https://www.chop.edu/centers-programs/vaccine-education-center/video/how-do-mrna-vaccines-work
Richardson, P., Griffin, I., Tucker, C., Smith, D., Oechsle, O., Phelan, A., Rawling, M., Savory, E., & Stebbing, J. (2020). Baricitinib as potential treatment for 2019-nCoV acute respiratory disease. The Lancet. Retrieved December 30, 2021, from https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)30304-4/fulltext
Redka, D., MacKinnon, S., Landon, M., Windemuth, A., Kurji, N., & Shahani, V. (2020). PolypharmDB, a Deep Learning-Based Resource, Quickly Identifies Repurposed Drug Candidates for COVID-19. ChemRxiv. doi:10.26434/chemrxiv.12071271.v1 This content is a preprint and has not been peer-reviewed.
Plant EP, Dinman JD. The role of programmed-1 ribosomal frameshifting in coronavirus propagation. Front Biosci. 2008 May 1;13:4873-81. doi: 10.2741/3046. PMID: 18508552; PMCID: PMC2435135.
Rahman MS, Rahman MK, Saha S, Kaykobad M, Rahman MS. Antigenic: An improved prediction model of protective antigens. Artif Intell Med. 2019 Mar;94:28-41. doi: 10.1016/j.artmed.2018.12.010. Epub 2019 Jan 3. PMID: 30871681.
UNMC. (2021, August 19). How long do mrna and Spike proteins last in the body? Nebraska Medicine. Retrieved December 30, 2021, from https://www.nebraskamed.com/COVID/where-mrna-vaccines-and-spike-proteins-go
Ransbotham, S., Khodabandeh, S., & Johnson, D. (2021). AI and the COVID-19 Vaccine: Moderna’s Dave Johnson. MIT Sloan Managment Review. other, Massachusetts Institute of Technology. Retrieved December 30, 2021, from https://sloanreview.mit.edu/audio/ai-and-the-covid-19-vaccine-modernas-dave-john
Heaton, Penny M. “The COVID-19 Vaccine-Development Multiverse: Nejm.” The New England Journal of Medicine, The New England Journal of Medicine, 12 Nov. 2020, https://www.nejm.org/doi/full/10.1056/NEJMe2025111.
Published
How to Cite
Issue
Section
Copyright (c) 2022 Abhinav Yarragunta
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Copyright holder(s) granted JSR a perpetual, non-exclusive license to distriute & display this article.
